Published in Drugs on January 01, 2011
Molecular and cellular analysis of human histamine receptor subtypes. Trends Pharmacol Sci (2012) 1.01
Radioprotective potential of histamine on rat small intestine and uterus. Eur J Histochem (2012) 0.87
TGF- β: an important mediator of allergic disease and a molecule with dual activity in cancer development. J Immunol Res (2014) 0.85
DNA-mediated adjuvant immunotherapy extends survival in two different mouse models of myeloid malignancies. Oncotarget (2015) 0.80
Selective cytoprotective effect of histamine on doxorubicin-induced hepatic and cardiac toxicity in animal models. Cell Death Discov (2015) 0.75
Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs (2004) 1.91
Atazanavir. Drugs (2003) 1.60
Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine (Gardasil). Drugs (2006) 1.27
Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2. Drugs (2002) 1.18
Remifentanil: a review of its use during the induction and maintenance of general anaesthesia. Drugs (2005) 1.18
Aprepitant: a review of its use in the prevention of chemotherapy-induced nausea and vomiting. Drugs (2004) 1.17
Darunavir: a review of its use in the management of HIV infection in adults. Drugs (2009) 1.16
Propofol: a review of its use in intensive care sedation of adults. CNS Drugs (2003) 1.16
Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs (2006) 1.12
Caspofungin: a review of its use in the treatment of fungal infections. Drugs (2005) 1.09
Imiquimod: in superficial basal cell carcinoma. Am J Clin Dermatol (2005) 1.08
Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis. BioDrugs (2002) 1.06
Insulin detemir: a review of its use in the management of type 1 and 2 diabetes mellitus. Drugs (2004) 1.06
Orlistat: a review of its use in the management of obesity. Drugs (2006) 1.04
Mirtazapine: a review of its use in major depression and other psychiatric disorders. CNS Drugs (2009) 1.04
Levofloxacin : a review of its use as a high-dose, short-course treatment for bacterial infection. Drugs (2008) 1.04
Imatinib mesylate: in the treatment of gastrointestinal stromal tumours. Drugs (2003) 1.02
Raltegravir. Drugs (2008) 1.01
Ertapenem: a review of its use in the treatment of bacterial infections. Drugs (2005) 0.99
Oxybutynin extended-release: a review of its use in the management of overactive bladder. Drugs (2004) 0.99
Prulifloxacin. Drugs (2004) 0.98
Topical imiquimod: a review of its use in the management of anogenital warts, actinic keratoses, basal cell carcinoma and other skin lesions. Drugs (2007) 0.98
Cetirizine: a review of its use in allergic disorders. Drugs (2004) 0.98
Lamotrigine: a review of its use in bipolar disorder. Drugs (2003) 0.97
Efavirenz/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen (Atripla®): a review of its use in the management of HIV infection. Drugs (2010) 0.96
Pentosan polysulfate: a review of its use in the relief of bladder pain or discomfort in interstitial cystitis. Drugs (2006) 0.96
Interferon-alpha-2b plus ribavirin: a review of its use in the management of chronic hepatitis C. Drugs (2002) 0.95
Brinzolamide : a review of its use in the management of primary open-angle glaucoma and ocular hypertension. Drugs Aging (2003) 0.94
Ramipril: a review of its use in the prevention of cardiovascular outcomes. Drugs (2002) 0.92
Octreotide long-acting release (LAR): a review of its use in the management of acromegaly. Drugs (2010) 0.92
Rasagiline: a review of its use in the management of Parkinson's disease. Drugs (2007) 0.91
Gliclazide modified release. Drugs (2002) 0.90
Cefepime: a review of its use in the management of hospitalized patients with pneumonia. Am J Respir Med (2003) 0.89
Dolutegravir: first global approval. Drugs (2013) 0.88
Fludarabine: a review of its use in non-Hodgkin's lymphoma. Drugs (2007) 0.87
Fixed-dose combination lercanidipine/enalapril. Drugs (2007) 0.87
Aripiprazole (ABILIFY MAINTENA®): a review of its use as maintenance treatment for adult patients with schizophrenia. Drugs (2014) 0.87
Tacrolimus once-daily formulation: in the prophylaxis of transplant rejection in renal or liver allograft recipients. Drugs (2007) 0.87
Micronised purified flavonoid fraction: a review of its use in chronic venous insufficiency, venous ulcers and haemorrhoids. Drugs (2003) 0.86
Topical bimatoprost: a review of its use in open-angle glaucoma and ocular hypertension. Drugs Aging (2002) 0.86
Fenofibric acid: in combination therapy in the treatment of mixed dyslipidemia. Am J Cardiovasc Drugs (2009) 0.86
Pemetrexed: a review of its use in the management of advanced non-squamous non-small cell lung cancer. Drugs (2009) 0.86
Spotlight on remifentanil for general anaesthesia. CNS Drugs (2005) 0.86
Rasburicase: a review of its use in the management of anticancer therapy-induced hyperuricaemia. Drugs (2006) 0.85
Simeprevir: first global approval. Drugs (2013) 0.85
Trastuzumab : in HER2 and hormone receptor co-positive metastatic breast cancer. Drugs (2007) 0.85
Abiraterone acetate: in metastatic castration-resistant prostate cancer. Drugs (2011) 0.84
Lopinavir/Ritonavir: a review of its use in the management of HIV-1 infection. Drugs (2010) 0.84
Everolimus. Drugs (2004) 0.84
Atomoxetine. Paediatr Drugs (2003) 0.83
Letrozole: a review of its use in postmenopausal women with breast cancer. Drugs (2004) 0.83
Tipranavir: a review of its use in the management of HIV infection. Drugs (2008) 0.83
Ciclesonide: a review of its use in the management of asthma. Drugs (2008) 0.83
Tacrolimus: in patients with rheumatoid arthritis. Drugs (2005) 0.83
Zoledronic acid: a review of its use in the treatment of osteoporosis. Drugs Aging (2008) 0.82
Emtricitabine: a review of its use in the management of HIV infection. Drugs (2005) 0.82
Drotrecogin alfa (activated). Drugs (2002) 0.82
Delayed-release Multi Matrix System (MMX) mesalazine: in ulcerative colitis. Drugs (2007) 0.82
Ramipril: a review of its use in preventing cardiovascular outcomes in high-risk patients. Am J Cardiovasc Drugs (2006) 0.82
Spotlight on lamotrigine in bipolar disorder. CNS Drugs (2004) 0.82
Topical dorzolamide 2%/timolol 0.5% ophthalmic solution: a review of its use in the treatment of glaucoma and ocular hypertension. Drugs Aging (2006) 0.82
Fosamprenavir: a review of its use in the management of antiretroviral therapy-naive patients with HIV infection. Drugs (2004) 0.82
Risedronate once a week. Treat Endocrinol (2003) 0.81
Gemtuzumab ozogamicin: a review of its use in acute myeloid leukaemia. Drugs (2005) 0.81
Transdermal oxybutynin: for overactive bladder. Drugs Aging (2003) 0.81
Metreleptin: first global approval. Drugs (2013) 0.81
Eplerenone: a review of its use in essential hypertension. Am J Cardiovasc Drugs (2005) 0.81
Estradiol valerate/dienogest. Drugs (2002) 0.81
Anakinra: a review of its use in the management of rheumatoid arthritis. BioDrugs (2005) 0.81
Alitretinoin: in severe chronic hand eczema. Drugs (2009) 0.80
Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy. Drugs (2004) 0.79
Spotlight on insulin detemir in type 1 and 2 diabetes mellitus. BioDrugs (2005) 0.79
Budesonide/formoterol: in chronic obstructive pulmonary disease. Drugs (2004) 0.79
Spotlight on amisulpride in schizophrenia. CNS Drugs (2002) 0.79
Glucosamine: a review of its use in the management of osteoarthritis. Drugs Aging (2003) 0.79
Oxycodone/Ibuprofen combination tablet: a review of its use in the management of acute pain. Drugs (2005) 0.78
Zoster vaccine live (Oka/Merck). Drugs Aging (2006) 0.78
Ibandronate: a review of its use in the management of postmenopausal osteoporosis. Drugs (2008) 0.78
Guanfacine extended-release: in attention deficit hyperactivity disorder. Drugs (2010) 0.78
Zonisamide: in Parkinson's disease. CNS Drugs (2009) 0.78
Danaparoid: a review of its use in thromboembolic and coagulation disorders. Drugs (2002) 0.78
Fondaparinux sodium: a review of its use in the prevention of venous thromboembolism following major orthopaedic surgery. Drugs (2004) 0.78
Rivaroxaban: a review of its use in the treatment of deep vein thrombosis or pulmonary embolism and the prevention of recurrent venous thromboembolism. Drugs (2014) 0.78
Aripiprazole: in acute mania associated with bipolar I disorder. CNS Drugs (2004) 0.78
Darunavir: in the treatment of HIV-1 infection. Drugs (2007) 0.78
Amoxicillin/clavulanic acid: a review of its use in the management of paediatric patients with acute otitis media. Drugs (2003) 0.77
Amphotericin B lipid complex: in visceral leishmaniasis. Drugs (2004) 0.77
Zidovudine: a review of its use in the management of vertically-acquired pediatric HIV infection. Paediatr Drugs (2002) 0.77
Fixed combination trandolapril/verapamil sustained-release: a review of its use in essential hypertension. Drugs (2002) 0.77
Romidepsin: in the treatment of T-cell lymphoma. Drugs (2011) 0.77
Enfuvirtide. Drugs (2003) 0.77
Spotlight on rasburicase in anticancer therapy-induced hyperuricemia. BioDrugs (2006) 0.77
Verteporfin: a review of its use in the management of subfoveal choroidal neovascularisation. Drugs Aging (2006) 0.77
Spotlight on histamine dihydrochloride in acute myeloid leukaemia. Drugs Aging (2011) 0.76
Spotlight on topical pimecrolimus in pediatric atopic dermatitis. Am J Clin Dermatol (2010) 0.76
Saxagliptin: a review of its use as combination therapy in the management of type 2 diabetes mellitus in the EU. Drugs (2012) 0.76
Bosentan. Am J Cardiovasc Drugs (2002) 0.76
Cabergoline : a review of its use in the treatment of Parkinson's disease. Drugs (2004) 0.76
Lamivudine/zidovudine/abacavir: triple combination tablet. Drugs (2003) 0.76